0

539730

FREDUN

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

Fredun Pharmaceuticals Limited Share Price Today

Investment Returns

Over 1 Month -10.76% Over 3 Months 34.01% Over 6 Months 36.63% Over 1 Year 203.84%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

Fredun Pharmaceuticals Limited fundamentals


  • Market cap (Cr) [-]
  • P/E Ratio (TTM) [-]
  • Beta [-]
  • Book Value / share [-]
  • Return on equity [-]%
  • EPS (TTM) [-]
  • Dividend yield [-]%
  • Net profit/quarter (Cr) [-]
info icon alternate text
  • Market cap (Cr) 1,276.20
  • P/E Ratio (TTM) 37.34
  • Beta 0.27
  • Book Value / share 514.65
  • Return on equity 15.83%
  • EPS (TTM) 60.24
  • Dividend yield [-]%
  • Net profit/quarter (Cr) 11.07
info icon alternate text

Fredun Pharmaceuticals Limited Financials

  • Key Results
  • Key Ratios
  • Balance sheet
  • Cash Flow
  • Competition
info-icon
Revenue
Net income
Particulars MAR 2026 (Values in Cr)
Revenue 210.41
Operating Expense 201.52
Net Profit 11.07
Net Profit Margin (%) 5.26
Earnings Per Share (EPS) 20.22
EBITDA 29.13
Effective Tax Rate (%) 4.07
Particulars DEC 2025 (Values in Cr)
Revenue 159.93
Operating Expense 146.92
Net Profit 10.48
Net Profit Margin (%) 6.55
Earnings Per Share (EPS) 22.19
EBITDA 26.33
Effective Tax Rate (%) 25.14
Particulars SEP 2025 (Values in Cr)
Revenue 143.59
Operating Expense 132.28
Net Profit 9.73
Net Profit Margin (%) 6.77
Earnings Per Share (EPS) 20.61
EBITDA 22.34
Effective Tax Rate (%) 25.13
Particulars JUN 2025 (Values in Cr)
Revenue 119.40
Operating Expense 110.81
Net Profit 6.77
Net Profit Margin (%) 5.67
Earnings Per Share (EPS) 14.33
EBITDA 16.99
Effective Tax Rate (%) 25.11
Particulars MAR 2025 (Values in Cr)
Revenue 165.44
Operating Expense 159.37
Net Profit 7.07
Net Profit Margin (%) 4.27
Earnings Per Share (EPS) 14.98
EBITDA 17.43
Effective Tax Rate (%) 12.06
Particulars MAR 2026 (Values in Cr)
Revenue 633.33
Operating Expense 591.54
Net Profit 33.21
Net Profit Margin (%) 5.24
Earnings Per Share (EPS) 68.01
EBITDA 94.78
Effective Tax Rate (%) 30.22
Particulars MAR 2025 (Values in Cr)
Revenue 451.71
Operating Expense 428.00
Net Profit 20.81
Net Profit Margin (%) 4.60
Earnings Per Share (EPS) 44.83
EBITDA 55.10
Effective Tax Rate (%) 26.38
Particulars MAR 2024 (Values in Cr)
Revenue 346.58
Operating Expense 327.62
Net Profit 15.62
Net Profit Margin (%) 4.50
Earnings Per Share (EPS) 33.32
EBITDA 38.90
Effective Tax Rate (%) 27.17
Particulars MAR 2023 (Values in Cr)
Revenue 274.34
Operating Expense 258.99
Net Profit 10.81
Net Profit Margin (%) 3.94
Earnings Per Share (EPS) 22.93
EBITDA 29.59
Effective Tax Rate (%) 38.26
Particulars MAR 2022 (Values in Cr)
Revenue 221.74
Operating Expense 217.48
Net Profit 6.34
Net Profit Margin (%) 2.85
Earnings Per Share (EPS) 14.29
EBITDA 15.43
Effective Tax Rate (%) 26.27
Particulars MAR 2025 (Values in Cr)
Book Value / Share 297.21
ROE % 13.96
ROCE % 15.97
Total Debt to Total Equity 1.18
EBITDA Margin 12.10
Particulars MAR 2025 (Values in Cr)
Book Value / Share 299.47
ROE % 15.83
ROCE % 18.72
Total Debt to Total Equity 1.03
EBITDA Margin 12.14
Particulars MAR 2024 (Values in Cr)
Book Value / Share 255.15
ROE % 14.34
ROCE % 16.95
Total Debt to Total Equity 0.88
EBITDA Margin 11.17
Particulars MAR 2023 (Values in Cr)
Book Value / Share 194.27
ROE % 13.15
ROCE % 17.43
Total Debt to Total Equity 0.85
EBITDA Margin 10.78
Particulars MAR 2022 (Values in Cr)
Book Value / Share 153.07
ROE % 11.41
ROCE % 12.90
Total Debt to Total Equity 0.83
EBITDA Margin 6.91
Particulars MAR 2021 (Values in Cr)
Book Value / Share 107.96
ROE % 4.76
ROCE % 9.34
Total Debt to Total Equity 0.88
EBITDA Margin 7.16
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 5.22
Total Assets 487.41
Total Liabilities 487.41
Total Equity 141.38
Share Outstanding 0
Price to Book Ratio 2.23
Return on Assets (%) 4.04
Return on Capital (%) 6.4
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 4.81
Total Assets 486.65
Total Liabilities 486.65
Total Equity 141.40
Share Outstanding 0
Price to Book Ratio 2.23
Return on Assets (%) 4.27
Return on Capital (%) 6.76
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 1.35
Total Assets 307.59
Total Liabilities 307.59
Total Equity 121.47
Share Outstanding 0
Price to Book Ratio 2.81
Return on Assets (%) 5.07
Return on Capital (%) 6.88
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 3.43
Total Assets 257.27
Total Liabilities 257.27
Total Equity 96.37
Share Outstanding 0
Price to Book Ratio 4.00
Return on Assets (%) 4.20
Return on Capital (%) 5.91
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 2.07
Total Assets 186.98
Total Liabilities 186.98
Total Equity 68.06
Share Outstanding 0
Price to Book Ratio 5.98
Return on Assets (%) 3.38
Return on Capital (%) 5.24
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 1.12
Total Assets 161.61
Total Liabilities 161.61
Total Equity 43.07
Share Outstanding 0
Price to Book Ratio 4.29
Return on Assets (%) 1.24
Return on Capital (%) 2.44
Particulars MAR 2025 (Values in Cr)
Net Income 20.03
Cash from Operations -29.06
Cash from Investing -6.35
Cash from Financing 39.11
Net change in Cash 3.69
Free Cash Flow -22.95
Particulars MAR 2025 (Values in Cr)
Net Income 20.80
Cash from Operations -28.88
Cash from Investing -5.99
Cash from Financing 38.34
Net change in Cash 3.46
Free Cash Flow -22.88
Particulars MAR 2024 (Values in Cr)
Net Income 15.62
Cash from Operations -0.43
Cash from Investing -7.63
Cash from Financing 5.99
Net change in Cash -2.08
Free Cash Flow 7.20
Particulars MAR 2023 (Values in Cr)
Net Income 10.75
Cash from Operations -14.40
Cash from Investing -9.40
Cash from Financing 25.17
Net change in Cash 1.36
Free Cash Flow -4.91
Particulars MAR 2022 (Values in Cr)
Net Income 6.31
Cash from Operations -2.38
Cash from Investing -4.14
Cash from Financing 7.46
Net change in Cash 0.94
Free Cash Flow 1.90
Particulars MAR 2021 (Values in Cr)
Net Income 2.01
Cash from Operations 0.16
Cash from Investing -1.38
Cash from Financing -0.71
Net change in Cash -1.93
Free Cash Flow 1.55
Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
AMBALAL SARABHAI ENT L 31.52 13.02 1.52 241.55 23.12 38.85
BLISS GVS PHARMA LTD. 436.05 35.28 3.86 4612.93 118.35 462.70
CIPLA LTD 1383.00 29.35 3.24 111725.01 1165.55 1672.20
FERMENTA BIOTECH LTD. 328.55 14.49 2.37 966.96 256.40 399.00
Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
AMBALAL SARABHAI ENT L 31.52 22.04 4.06 241.55 23.12 38.85
AMRUTAJAN HEALTH LTD 562.65 25.22 4.39 1626.66 490.00 789.95
ASTRAZENECA PHARMA INDIA LTD. 8248.80 107.73 23.62 20622.00 7630.00 10653.05
BLISS GVS PHARMA LTD. 436.05 46.89 3.99 4612.93 118.35 462.70

Fredun Pharmaceuticals Limited shareholding pattern

Holding
51.94%
44.16%
1.06%
2.83%
Name Shares Category
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)

News

Left Arrow
Right Arrow

Fredun Pharmaceuticals Limited Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
2314.95 2.90 redarrow
red-green-graph indicator
7 Bearish
9 Bullish
  • 5 Days 2297.90
  • 26 Days 2309.30
  • 10 Days 2324.30
  • 50 Days 2192.00
  • 12 Days 2330.50
  • 100 Days 1994.70
  • 20 Days 2329.10
  • 200 Days 1732.20
2278.18 PIVOT
First Support 2197.37 First Resistance 2330.37 Second Support 2145.18 Second Resistance 2411.18 Third Support 2064.37 Third Resistance 2463.37
RSI 45.71 ADX 17.07 MACD 21.16 Williams % R -82.93 Commodity Channel Index (CCI) -110.73
Date 2026-06-11 Week 4904.00 Same Day 4677.00 Month 8910.00
1 Year 0.27 3 Year 0.52
Over 1 Month
-10.76% down
Over 1 Year
203.84% down
Over 3 Months
34.01% down
Over 3 Years
38.44% down
Over 6 Months
36.63% down
Over 5 Years
39.48% down

Fredun Pharmaceuticals Limited Corporate Actions

Dividend date Dividend amount Dividend type Record date Instrument type
23 Jun 2026 0.7 Final 23 Jun 2026 Equity shares
23 Sep 2025 0.7 Final 23 Sep 2025 Equity shares
23 Sep 2024 0.7 Final 23 Sep 2024 Equity shares
22 Sep 2023 0.7 Final 22 Sep 2023 Equity shares
16 Sep 2021 0.7 Final 18 Sep 2021 Equity shares
16 Sep 2019 0.65 Final 18 Sep 2019 Equity shares
18 Sep 2018 0.6 Final 21 Sep 2018 Equity shares
20 Sep 2017 0.6 Final 22 Sep 2017 Equity shares
11 Apr 2016 0.6 Interim 13 Apr 2016 Equity shares

Top Gainers

Top Losers

stock
Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of Fredun Pharmaceuticals Ltd?

Answer Field

Fredun Pharmaceuticals Ltd share price is for NSE ₹ 0.00 & for BSE ₹ 2,314.95 as on Jun 12 2026 03:29 PM.

What is the Market Cap of Fredun Pharmaceuticals Ltd Share?

Answer Field

The market cap of Fredun Pharmaceuticals Ltd for NSE ₹ 0.00 & for BSE ₹ 1,276.20 as on Jun 12 2026 03:29 PM.

What is the 52 Week High and Low of Fredun Pharmaceuticals Ltd?

Answer Field

The 52 Week High and Low of Fredun Pharmaceuticals Ltd for NSE is ₹ 0.00 and ₹ 0.00 and for BSE is ₹ 2,620.00 and ₹ 720.25.

What is 1 year return for Fredun Pharmaceuticals Ltd?

Answer Field

The 1 year returns on the stock has been 203.84%.

What is the P/E Ratio of Fredun Pharmaceuticals Ltd Share?

Answer Field

As on Jun 12 2026 03:29 PM the price-to-earnings (PE) ratio for Fredun Pharmaceuticals Ltd share is 37.34.

What is the PB ratio of Fredun Pharmaceuticals Ltd Share?

Answer Field

As on Jun 12 2026 03:29 PM, the price-to-book (PB) ratio for Fredun Pharmaceuticals Ltd share is 514.65.

How to Buy Fredun Pharmaceuticals Ltd Share?

Answer Field

You can trade in Fredun Pharmaceuticals Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Fredun Pharmaceuticals Ltd Share on Bajaj Broking App?

Answer Field

To buy Fredun Pharmaceuticals Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Fredun Pharmaceuticals Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

close-image

Get Free Demat Account*

+91
close-img

Authorise with OTP

Enter the 4-Digit OTP sent to
edit
OTP expires in 00:59
banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|